Evidence map›Paper›PMID 40534602›Full record

ArticleFrontiers in toxicology2025

Characterization of medical device constituents and development of duration-based non-cancer threshold of toxicological concern values.

Taylor Builee, Todd A Kennedy, Valériane Levelut, Megan A Hahn, Stephen Bond, Michael K Peterson, Frances K Hsia, Alessia Stornetta, Kristin J Erickson, Kimberly D Ehman and 3 more

Abstract read
In one paragraph

Article in Frontiers in toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Taylor BuileeToxicology Consultant, Princeton, NJ, United States.
Todd A KennedyW.L. Gore and Associates, Inc., Flagstaff, AZ, United States.
Valériane LevelutNAMSA, Biological Safety and Consulting, Chasse-sur-Rhône, France.
Megan A HahnNAMSA, Biological Safety and Consulting, Northwood, OH, United States.
Stephen BondRMQ+, Jordi Labs, Mansfield, MA, United States.
Michael K PetersonGradient, Seattle, WA, United States.
Frances K HsiaBoston Scientific Corporation, Preclinical Sciences, Arden Hills, MN, United States.
Alessia StornettaBoston Scientific Corporation, Preclinical Sciences, Arden Hills, MN, United States.
Kristin J EricksonWuXi AppTec, St. Paul, MN, United States.
Kimberly D EhmanWuXi AppTec, St. Paul, MN, United States.
Bindu PrabhakarWuXi AppTec, St. Paul, MN, United States.
Bradford D BagleySolventum, Product Stewardship, St. Paul, MN, United States.
Sherry P ParkerSParker Toxicology Consulting LLC, Davie, FL, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: In the absence of sufficient constituent-specific dose-response toxicity data, threshold of toxicological concern (TTC) values are commonly used in toxicological risk assessment of medical device (MD) constituents. When experimental data or predictions suggest that a constituent is not likely to have genotoxic effects, categorizing the constituent into its appropriate Cramer Class and application of the corresponding TTC value is recommended. This paper presents the uniqueness of the MD chemical space when compared to the historical Munro TTC dataset via structure-based chemical taxonomy, ToxPrint chemotypes, physicochemical properties and molecular descriptors, and proposes duration-based MD non-cancer TTC values. Methods: More than 15,000 MD constituents were identified and screened, and 790 constituents met the established criteria for inclusion. Constituents with chemotypes matching inorganic substances, metals, pharmacologically active, nitroso-like, aflatoxin-like, azoxy, benzidine, polyhalogenated dibenzodioxins, dibenzofurans, biphenyls, high molecular weight polymers, nanomaterials, proteins, and radioactive substances were excluded from the evaluation. Constituent-specific toxicity data were obtained from the data-rich and open-access, European Chemicals Agency Registration, Evaluation, Authorisation and Restriction of Chemicals (ECHA REACH) database. Considered protective for systemic, developmental, and reproductive toxicity, constituent-specific oral no-observed-adverse-effect-level (NOAEL) values from repeated dose studies with a reliability (Klimisch) score of 1 or 2 were selected as the point of departure (POD) for each duration (subacute/subchronic/chronic/lifetime). The NOAEL values selected as PODs for each constituent in each duration category were plotted using log-normally fitted cumulative frequency distributions, and an uncertainty factor of 100 (10 each for inter and intraspecies differences) was applied to the lowest fifth percentile NOAEL value extrapolated from each curve. Results: The resulting non-cancer TTC values for various exposure duration categories were 112 μg/kg/day for ≤ 1 day to 30 days, 111 μg/kg/day for 31 to 365 days and 41 μg/kg/day for ≥ 366 days. Discussion: The proposed MD non-cancer TTC values followed the same approach as derivation of the Munro TTC values; however, they are derived exclusively from MD constituents with chemical-specific data for the appropriate period of assumed exposure to the constituent.

Indexed as

fit for purposeless than lifetimemedical devicenon-cancerthreshold of toxicological concern

Identifiers

PMID40534602
PMCPMC12175843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.